BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES - Revenues disaggregated by our business operations and timing of revenue recognition (Details) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES
Total	$ 13,367,443	$ 18,168,677
LineaRx, Inc.
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES
Percentage of ownership held in Subsidiary	98.00%
Research and development services (over-time)
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES
Total	$ 421,585	592,001
Clinical laboratory testing services (point-in-time)
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES
Total	7,612,975	10,398,782
Clinical laboratory testing services (over-time)
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES
Total	3,540,456	5,127,953
Supply chain
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES
Total	827,603	887,061
Large Scale DNA Production
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES
Total	653,015
Asset marking
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES
Total	$ 311,809	534,594
MDx test kits and supplies
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES
Total		$ 628,286